ANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $70.80, for a total value of $35,400.00. Following the transaction, the vice president owned 72,924 shares in the company, valued at $5,163,019.20. This trade represents a 0.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Tuesday, October 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $73.59, for a total transaction of $36,795.00.
• On Monday, September 14th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $70.79, for a total transaction of $35,395.00.

ANI Pharmaceuticals Price Performance

Shares of ANIP traded up $0.46 during mid-day trading on Friday, hitting $71.52. 243,184 shares of the company were exchanged, compared to its average volume of 390,162. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.33 and a current ratio of 2.75. ANI Pharmaceuticals, Inc. has a 1-year low of $67.14 and a 1-year high of $87.76. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of 14.25, a price-to-earnings-growth ratio of 2.29 and a beta of 0.45. The company has a 50 day moving average of $72.33 and a 200-day moving average of $77.05.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.18 by $0.52. The company had revenue of $290.78 million for the quarter, compared to analysts’ expectations of $280.59 million. ANI Pharmaceuticals had a net margin of 11.22% and a return on equity of 28.34%. The firm’s quarterly revenue was up 27.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.04 EPS. Analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current fiscal year.

Analyst Ratings Changes

ANIP has been the subject of a number of analyst reports. Canaccord Genuity Group dropped their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Oppenheimer began coverage on ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price objective on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Wednesday, November 4th. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Hold” and a consensus price target of $100.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. KBC Group NV purchased a new stake in ANI Pharmaceuticals in the first quarter valued at $28,000. Versant Capital Management Inc lifted its stake in shares of ANI Pharmaceuticals by 103.3% in the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 217 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at $32,000. USA Financial Formulas acquired a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at $39,000. Finally, Sterling Capital Management LLC grew its holdings in shares of ANI Pharmaceuticals by 850.0% during the 3rd quarter. Sterling Capital Management LLC now owns 684 shares of the specialty pharmaceutical company’s stock worth $50,000 after purchasing an additional 612 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.